Loading...
Loading...
LUNG| Name | Value |
|---|---|
| Revenues | 19.3M |
| Cost of Revenue | 5.0M |
| Gross Profit | 14.3M |
| Operating Expense | 28.2M |
| Operating I/L | -13.9M |
| Other Income/Expense | 0.3M |
| Interest Income | 1.5M |
| Pretax | -13.6M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -13.9M |
Pulmonx Corporation is a medical technology company specializing in minimally invasive devices for treating chronic obstructive pulmonary diseases. Its flagship products include the Zephyr Endobronchial Valve, designed to treat severe emphysema in adult patients with hyperinflation, and the Chartis Pulmonary Assessment System, which assesses collateral ventilation. Additionally, the company offers the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that provides crucial information for identifying target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients globally, generating revenue through the sale of its innovative medical devices and related services.
